Chemotherapy-Induced Nausea and Vomiting – Can We Make It a Thing of the Past?

Meeting Overview

We are pleased to invite you to our satellite symposium, Chemotherapy-Induced Nausea and Vomiting – Can We Make It a Thing of the Past?, a prIME Oncology symposium, to be held on May 5, 2017, in Denver, Colorado. This interactive activity will provide an overview of chemotherapy-induced nausea and vomiting (CINV) pathophysiology, risk assessment, and current and emerging treatment options.

Meeting space has been assigned to provide symposia supported by Helsinn Oncology and TESARO, Inc., during the Oncology Nursing Society’s (ONS) 42nd Annual Congress, May 4 – 7, 2017, in Denver, Colorado. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.


5.45 AM Breakfast and registration
6.00 AM Welcome and introductions
Rebecca Clark-Snow, RN, BSN, OCN
6.02 AM Beat the experts quiz on the management of CINV
Rebecca Clark-Snow, RN, BSN, OCN
6.07 AM Why patients experience nausea and vomiting and what to do about it
Rebecca Clark-Snow, RN, BSN, OCN
6.22 AM Questions
6.25 AM Opportunities to avoid CINV in 2017
Charles Loprinzi, MD
6.40 AM Questions
6.45 AM The integration of clinical guidelines and personalized medicine to optimize patient care
Rita Wickham, PhD, RN, AOCN
7.00 AM Questions
7.05 AM Patient-focused care to help your patients through chemotherapy and radiotherapy
Nicole Edwards, MSN, APN, FNP-BC
7.25 AM Concluding remarks and prIME Points™
Rebecca Clark-Snow, RN, BSN, OCN
7.30 AM Adjourn


  • Rebecca Clark-Snow, RN, BSN, OCNThe University of Kansas Cancer Center
    Westwood, Kansas, United States
  • Nicole Edwards, MSN, APN, FNP-BCWest Cancer Center
    Memphis, Tennessee, United States
  • Charles Loprinzi, MDMayo Clinic
    Rochester, Minnesota, United States
  • Rita Wickham, PhD, RN, AOCNRush University College of Nursing
    Chicago, Illinois, United States

*Additional faculty to be confirmed

Target Audience

This educational activity is specifically designed to meet the needs of oncology nurses and other healthcare professionals involved in the treatment of patients with CINV.

Learning Objectives

  • Describe the physiologic principles underlying CINV and radiotherapy-induced nausea and vomiting
  • Identify current guideline-based treatments and the unmet medical need for further improvements in CINV management
  • Assess the potential use of a CINV risk factor tool kit to refine treatment and optimize individual patient management
  • Evaluate the most current clinical data on prevention and treatment of CINV, with an emphasis on long-acting neurokinin 1 (NK-1) receptor antagonists


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

Register Now

Date and Location

Friday, May 5, 2017
5.45 AM – 7.30 AM

Centennial Ballrooms F-H
Hyatt Regency Denver Convention Center
650 15th Street
Denver, Colorado 80202


This activity is provided by prIME Oncology.

Continuing Education

This continuing nursing education activity was approved by the ONS, an accredited approver by the American Nurses Credentialing Center’s COA.

Content in this learning activity is applicable to meeting individual requirements for certification renewal through the Oncology Nursing Certification Corporation’s Independent Learning Needs Assessment (ILNA) renewal method.  Visit for complete details on oncology nursing certification.

This activity has been approved for 1.47 contact hours.


This educational activity is supported by grants from Helsinn Oncology and TESARO, Inc.